This newsletter presents you the following key sessions:
1. First-line pembrolizumab plus chemotherapy confirms durable clinical benefit after 5 years in patients with
metastatic NSCLC and negative PD-L1 expression
2. High rates of durable responses with sacituzumab govitecan plus pembrolizumab as first-line treatment for
patients with metastatic non-small cell lung cancer
3. Consensus definition of resectable stage III non-small cell lung cancer: A multidisciplinary initiative
4. Durvalumab consolidation therapy in EGFR-mutated NSCLC patients: Real-World insights from the
PACIFIC-R study
5. First-line osimertinib plus chemotherapy outperforms osimertinib monotherapy in the treatment of patients
with advanced NSCLC harbouring EGFR mutations